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Abstract Objective: Heart failure treatment in general
practice is not concordant with guideline recommenda-
tions. Insight into the key determinants at diﬀerent levels
is needed in order to improve care. The aim was to assess
the inﬂuence of physician, organisational and patient
characteristics on the treatment of chronic heart failure
with angiotensin converting enzyme (ACE) inhibitors in
primary care.
Methods: Physician and organisational data were col-
lected by means of a questionnaire. Patient and treat-
ment data were extracted from electronic medical
records. Multilevel analysis was used to assess the eﬀect
of physician, organisational and patient factors on the
treatment with ACE inhibitors in terms of prescription
rate and dosage.
Results: Data from 735 randomly selected heart failure
patients were extracted from the medical records of 95
general practitioners (GPs). Patients who visited a car-
diologist or an outpatient heart failure clinic were more
likely to receive an ACE inhibitor. In addition, relatively
young patients, male patients and patients already using
a diuretic were more likely to receive an ACE inhibitor.
Furthermore, male patients and patients with concomi-
tant hypertension were more likely to receive a higher
dose of ACE inhibitor. GP characteristics did not
determine whether CHF patients received ACE inhibitor
treatment.
Conclusion: The diﬀerences in ACE inhibitor prescribing
seem to be linked more to patient than physician char-
acteristics. Interventions to improve the quality of care
should therefore focus on the treatment of speciﬁc pa-
tient groups. Specialised care, particularly through out-
patient clinics, could lead to improvement in the use of
ACE inhibitors.
Introduction
Most guidelines on the management of chronic heart
failure (CHF) recommend angiotensin converting en-
zyme (ACE) inhibitors as standard therapy for all pa-
tients [1]. Also, in patients whose diagnosis is based on
signs and symptoms, as is usually the case in Dutch
general practice, ACE inhibitors are considered stan-
dard long-term therapy after starting treatment with
diuretics [2]. Although treatment pattern diﬀers between
countries [3], ACE inhibitors are generally underused
and under-dosed in general practice [4–6].
Surveys have revealed a number of problems that
general practitioners (GPs) perceive for optimal CHF
management, such as diﬃculties with establishing an
accurate diagnosis, lack of time and available resources,
poor communication between primary and secondary
care, and fear or reluctance to initiate ACE inhibitors in
elderly and frail patients or patients already on diuretics
[7–10]. Other studies focused particularly on specialist
type or organisational factors, indicating that
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cardiologists prescribe ACE inhibitors both more fre-
quently and in a higher dosage than GPs do, and that
patients attending heart failure clinics receive more
adequate doses of ACE inhibitor than those in primary
care [11–13]. Furthermore, several patient characteristics
seem to be associated with heart failure management.
Female and elderly patients were less likely to be re-
ferred to a specialist or to a hospital outpatient clinic,
had less access to echocardiography and received less
ACE inhibitor treatment [3, 14–16].
Most of these studies did not look at the combined
inﬂuence of physician, organisational and patient fac-
tors, although it has been shown that there can be rel-
evant diﬀerences in patient population at the physician
or organisational level [12, 17]. Also within one level,
characteristics such as the patient’s age and gender are
clearly related in the way they aﬀect the management of
heart failure [15]. Therefore, it is important to examine
all variables simultaneously.
The aim of this study was to assess the inﬂuence of
physician, organisational and patient characteristics on
the quality of CHF treatment in primary care, focusing
on the use and dosage of ACE inhibitors.
Methods
Study design and population
This study was part of the baseline of a larger study
conducted from September 2001 to May 2002 in the
north of the Netherlands, evaluating two audit pro-
grams for peer review groups focusing on the treatment
of CHF and treatment of hypertension in diabetic pa-
tients [18].
The study was conducted in 21 peer-review groups
with 150 GPs, of whom 95 GPs participated in this
study. Physician and organisational characteristics were
measured by a structured questionnaire. Patients with
the following inclusion criteria were selected: all patients
with a diagnostic code or the text ‘heart failure’, ‘cardiac
asthma’, ‘cardiac decompensation’ or ‘left ventricular
dysfunction’ in their medical records. From this list, a
random sample of ten CHF patients per GP or practice
was selected. All cases were screened to exclude both
misclassiﬁcation and those patients with diabetes mell-
itus as comorbidity. These patients were excluded be-
cause they fell into both the control and intervention
group for the larger study. The GPs were asked to verify
the CHF diagnosis.
Patient data were extracted by trained data extractors
from GPs computerised medical records. Data were
collected on prescriptions of cardiovascular medication,
possible contra-indications for cardiovascular drugs and
previous medication problems mentioned in the medical
record. All prescriptions with a start date no more than
6 months prior to data collection were included. These
data were recorded anonymously on a printed form
which included the patient’s sex and birth date. At the
time of the study, no informed consent from patients
was needed for this study.
Outcome variables
The ﬁrst outcome measure focused on whether an ACE
inhibitor was prescribed or not. The second outcome
measure was the average standardised dosage of the
ACE inhibitors prescribed. ACE inhibitor dosages were
converted to enalapril-equivalent dosages according to
the target daily doses recommended for heart failure in
the Dutch reference desk book. This method has been
used previously [19] and uses enalapril 20 mg as refer-
ence dose with equivalent doses of captopril 150 mg,
ramipril 10 mg, quinapril 20 mg, lisinopril 20 mg, fos-
inopril 40 mg and perindopril 4 mg.
Determinants
Determinants included at the physician level were the
GPs’ gender, work experience (<10 years, 10–20 years,
>20 years) and dispensing status (whether or not the
GP is allowed to dispense drugs him/herself). Size and
type of the practice (single-handed versus partnership)
and location of the practice (urban, semi-urban or rural)
were measured as organisational characteristics at the
physician level. Organisational factors included at pa-
tient level were visits to a CHF outpatient clinic and
hospitalisations in the previous year, and referrals to a
cardiologist. Patient demographics included were age
(<85 years or ‡85 years) and gender. Other patient
characteristics included were comorbidities documented
in the medical record, such as cerebrovascular disease
(stroke, transient ischaemic attack), hypertension, angi-
na, peripheral vascular disease, atrial ﬁbrillation, and
the presence of chronic obstructive pulmonary disease
(COPD) or asthma. In addition, serum creatinine above
normal levels (>80 lmol/l for females and >110 lmol/l
for males) and the use of a diuretic were included as
factors, which may inﬂuence the choice of treatment.
The use of diuretic was included since GPs have indi-
cated that these drugs may form a barrier for prescribing
an ACE inhibitor [20]. Finally, the objectivity of the
diagnosis of heart failure was included in the model,
since we included all patients who were diagnosed with
CHF based on criteria deﬁned by the GPs. An objective
diagnosis was deﬁned as having a registered ejection
fraction below 40% and/or an echocardiography indi-
cating heart failure or left ventricular dysfunction.
Statistical analysis
Multilevel analysis was used to assess the inﬂuence of all
characteristics simultaneously on each of the outcome
variables. A two-level random intercept model was esti-
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mated, taking into account the clustering of patients
within the practice of a GP. Logistic regression was used
for treatment with an ACE inhibitor as a dichotomous
outcome variable. To estimate the eﬀect of the determi-
nants on average ACE inhibitor dosage, a regression
model was built with the standardised dosage as a con-
tinuous outcome variable [21].
The intra-class correlation coeﬃcient (ICC) was cal-
culated to assess the variance at the physician level.
When the ICC is nearly zero, a non-hierarchical
regression model can be used. To evaluate whether the
determinants in the model are a good ﬁt for predicting
the outcome variable, the deviance test was used com-
paring the ﬁnal with the empty two-level model.
A possible interaction eﬀect between age and gender
of the patient was built into the treatment model, be-
cause it is known that older women in particular may
receive more diuretics and fewer ACE inhibitors [14].
The inﬂuence of the cardiologist was analysed in two
separate models—one including only referrals during the
last year and one including all referrals during the last
3 years. This was done because a patient in The Neth-
erlands may remain under the care of a cardiologist for
longer periods without a new referral. Descriptive
analyses were performed with SPSS 10 and multilevel
analysis was analysed using MLwin1.2 [21].
Results
Characteristics of the population
Most of the 95 GPs were male (86%) and their mean age
was 47 years (Table 1). The majority worked in a single-
handed practice (59%) and in a rural area (63%). The
theoretical number of 950 patients was not achieved, as
not all practices could provide ten CHF patients due to
the fact that some practices had a relatively young pa-
tient population. Furthermore, patients with a comor-
bidity of diabetes and misclassiﬁed patients were
excluded. Of the remaining 735 CHF patients, 52% was
male and their mean age was 76 years (Table 2). The
average recorded duration of their heart failure was
3.3 years. An objective diagnosis (based on ejection
fraction or echocardiography) was recorded for 78 pa-
tients (11%). In the previous year, 33% had been re-
ferred to a cardiologist; whereas 49% had a referral in
the last 3 years. Only 3% visited an outpatient heart
failure clinic.
Most CHF patients (67%) received a diuretic (Ta-
ble 2); 47% were treated with ACE inhibitors and an-
other 8% received an angiotensin-II antagonist. A
noteworthy proportion of patients (10%) did not receive
any CHF drug treatment. These patients had been re-
ferred to a cardiologist less often (18% in the previous
year). The medical history of four patients not receiving
an ACE inhibitor reported cough as the reason for
stopping ACE inhibitor use. Other side eﬀects were
mentioned for another four patients as reasons to stop
using an ACE inhibitor. For six patients, ACE inhibitors
were discontinued without a documented reason in their
medical record.
Characteristics associated with ACE inhibitor therapy
The intra-class correlation coeﬃcient (ICC = 0.061) in
the multilevel model showed that there were diﬀerences
















Table 2 Patient characteristics as registered in the medical records
(n = 735). ACE angiotensin converting enzyme, COPD chronic
obstructive pulmonary disease, CHF chronic heart failure
Mean±SD n %
Age (years) 76.3±11.4 735
Creatinine (lmol/l) 123.6±67.7 248
Potassium (mmol/l) 4.3±0.6 207
Objective diagnosis a 78 10.6
Duration of CHF (years) 3.3±3.2 446
Male 382 52.0
Ejection fraction 35.1±14.1 43
Cerebrovascular disease 54 7.3
Myocardial infarction 188 26
Angina pectoris 207 28
Atrial ﬁbrillation 240 33
Hypertension 235 32
Peripheral vascular disease 32 4









in previous three years
361 49
Care by outpatient heart




ACE inhibitor 342 47
AII-antagonist 58 8
No medication 76 10
a Patients with a documented ejection fraction below 40% and/or
an echocardiography conﬁrming heart failure or left ventricular
dysfunction
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between GPs in prescribing frequency of ACE inhibi-
tors. The deviance test for this treatment model was
signiﬁcant (Table 3, Chi-square = 50.13, df = 23, P <
0.001).
One organisational factor had a signiﬁcant impact
after adjusting for patient characteristics. Patients who
visited a heart failure outpatient clinic had a higher
chance of being prescribed an ACE inhibitor. In the
model including all referrals to a cardiologist in the
previous 3 years, patients who had been referred were
also more likely to receive an ACE inhibitor. In the
model including only referrals during the last year, this
factor did not reach signiﬁcance (model not shown). In
this model, however, patients from dispensing GPs were
found to be more likely to receive an ACE inhibitor
(odds 1.64; 95% CI 1.04–2.61, model not shown). In
both models, male patients, patients aged less than
85 years and patients who were using a diuretic had a
higher probability of receiving an ACE inhibitor
(Table 3).
Characteristics associated with ACE inhibitor dosage
Of the 320 patients who received an ACE inhibitor for
which the dosage was registered, the average enalapril-
equivalent dose was 13.5 mg. In the multilevel model
predicting the ACE inhibitor dosage, the intra-class
correlation coeﬃcient was 0.018. The deviance test
showed that the multilevel model including all factors
did not provide a signiﬁcant ﬁt (Chi-square = 16.47, df
= 23, P > 0.05). None of the determinants at the
physician or practice level contributed to explaining the
diﬀerences in dosages prescribed. Therefore, the results
of a linear regression model at the patient level are
presented (Table 3). After adjustment for other patient
characteristics—including age—male patients were more
likely to receive a high dosage than female patients.
CHF patients with an additional comorbidity of
hypertension were more likely to receive higher dosages
of the ACE inhibitor.
Table 3 Physician, organisational and patient factors predicting treatment with and dosage of angiotensin converting enzyme (ACE)
inhibitors. COPD chronic obstructive pulmonary disease
Multilevel logistic model
for treatment with ACE









Gender (male) 1.15 (0.64–2.07)
Work experience <10 years 1.00
Work experience 10–20 years 0.79 (0.48–1.29)
Work experience >20 years 1.10 (0.68–1.76)
Dispensing 0.63 (0.39–1.01)
Organisational characteristics
Practice type (single-handed) 1.33 (0.85–2.09)
Practice location urban 1.00
Practice location semi-urban 1.29 (0.62–2.67)
Practice location rural 1.32 (0.77–2.26)
Practice size 1.00 (0.99–1.00)
Patient level
Patient characteristics
Age (‡85 years) 0.55* (0.35–0.85) 1.98 (1.54–5.50)
Gender (male) 1.60* (1.13–2.27) 2.69* (0.20–5.19)
Objective diagnosis 1.48 (0.98–2.81) 1.70 (5.52–2.12)
Myocardial infarction 0.86 (0.57–1.28) 1.70 (4.50–1.10)
Hypertension 1.29 (0.90–1.85) 4.87* (2.35–7.40)
Peripheral vascular disease 0.78 (0.33–1.84) 2.10 (4.34–8.55)
Atrial ﬁbrillation 1.20 (0.84–1.70) 0.81 (3.34–1.71)
Angina pectoris 0.95 (0.65–1.40) 1.98 (4.67–0.70)
COPD or asthma 0.87 (0.61–1.26) 0.99 (3.63–1.65)
Cerebrovascular diseases 0.77 (0.41–1.45) 3.22 (8.03–1.60)
Creatinine>normal 1.19 (0.79–1.78) 1.22 (3.97–1.52)
Diuretic 1.89* (1.32–2.71) 2.27 (5.03–0.50)
Interaction term gender-age 0.50 (0.21–1.18)
Organisational characteristics
Hospitalisation 1.40 (0.90–2.19) 1.27 (4.26–1.72)
Outpatient heart failure clinic 4.58* (1.45–14.47) 2.78 (3.25–8.81)
Referral to cardiologist (<3 years) 1.85* (1.28–2.68) 1.37 (3.83–1.09)
*Signiﬁcant at P<0.05 level
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Discussion
Summary of main ﬁndings
Underuse and under-dosing of ACE inhibitors were
mainly associated with patient characteristics, such as
gender, age, concomitant hypertension and the use of a
diuretic. Organisational factors as specialist care and
outpatient heart failure clinics were also associated with
higher prescribing of ACE inhibitors. General GP
characteristics, such as work experience or gender, did
not determine whether heart failure patients received
ACE inhibitor treatment.
Strengths and limitations
Quality of care may be inﬂuenced by factors that are
related to the patients, the physicians or the way that the
care is organised. In this study, these characteristics were
studied in one model thereby taking into account pos-
sible confounding factors at diﬀerent levels.
Our study does have some limitations. The popula-
tion of GPs in our study, including a relative large
proportion of single-handed, male, dispensing GPs, is
typical for our region. This regional selection may
inﬂuence drawing conclusions about the quality of
treatment in general, but it does not limit the analysis of
factors inﬂuencing this quality. Excluding the subgroup
of CHF patients with concomitant diabetes from our
study forms a limitation since ACE inhibitors are pre-
scribed more frequently in this group of patients [5]. The
use of medical records implies that only clinical infor-
mation known and considered relevant by the GPs has
been included; therefore under-recording of normal
ﬁndings in particular was likely [12]. In our analyses, we
assumed that no registered measurement implied no
abnormal ﬁnding, but some of these patients may have
had an undocumented abnormal ﬁnding. Prescriptions
were made electronically by the GPs in our study and
were automatically recorded in the medical records.
Initial prescriptions of specialists may have been missed;
in the Netherlands, it is common for chronic medication
started by a specialist to be continued by the GP and
recorded in the medical records. In the case of dispens-
ing GPs, initial prescriptions of specialists are more of-
ten included in the GPs’ medical records. Data on
ejection fraction, i.e. on an objective diagnosis of CHF,
were available for only a few patients. This reﬂects
reality in primary care in The Netherlands, where GPs
tend to diagnose heart failure on clinical grounds, sup-
ported by a diagnostic trial of diuretics [22]. In the
European IMPROVEMENT-HF study in primary care,
only 10% of Dutch primary care physicians would ask
for an echocardiography [3]. This may be a consequence
of the older Dutch general practice guideline (1995) that
still stated, at that time, that echocardiography is of
limited value for the diagnosis of heart failure. However,
the newer guideline (2002) does indicate the need for
echocardiography, as well as open access of GPs to
echocardiography. In addition, when diagnostics have
been performed (as is the case in referred patients), it
seems that GPs do not record such data adequately in
the (computerised) medical records [3]. In this study, we
sought to examine the current prescription for those
patients the GP considered as having CHF. We focused
on the prescription of ACE inhibitors only. The results
of this study can therefore not be extrapolated to the
overall treatment of CHF. The use of ACE inhibitors,
however, is one of the relevant performance indicators
for CHF [23, 24].
Comparison with existing literature
A beneﬁcial eﬀect on the use of ACE inhibitors could be
demonstrated when patients had attended an outpatient
heart failure clinic, although this involved only a small
percentage of patients. It has been suggested that, given
the complicated treatment of heart failure and comorbid
diseases, heart failure clinics with their multifaceted
approach may be better equipped for treating CHF
patients than GPs alone [25]. Our ﬁndings also show
that previously described diﬀerences observed in treat-
ment patterns between GPs and cardiologists remain
signiﬁcant after adjustment for diﬀerences in patient
population. Patients with a referral to a cardiologist in
the last 3 years were more likely to receive an ACE
inhibitor. The ﬁnding that patients of dispensing GPs
received more ACE inhibitors when only including
referrals in the previous year may be an artefact related
to the fact that initial prescriptions of specialists are
more often included in the medical record of these dis-
pensing GPs.
The diagnosis of heart failure in general practice is
often based on symptoms and signs [22]. Echocardiog-
raphy is not as readily available in The Netherlands as in
other countries such as the UK [26]. In our study, the
recording of an objectively made diagnosis based on an
echocardiography or ejection fraction was associated
with a somewhat higher use of ACE inhibitors, but this
was not signiﬁcant. It should be noted, however, that we
adjusted for specialist care, and there were only nine
patients who had an objective diagnosis without such
specialist care.
The ﬁnding that elderly patients were prescribed
fewer ACE inhibitors than younger patients has been
shown several times before. The GPs seem reluctant to
prescribe these drugs in heart failure patients aged
85 years and over, despite recent ﬁndings showing their
beneﬁts in very old and frail patients [27]. After adjust-
ing for age, female patients were also less likely to re-
ceive ACE inhibitors. This is in contrast to a previous
study where the inﬂuence of gender decreased after
controlling for age [16], but in line with a large inter-
national study [3]. Our ﬁndings did not support the
concept that women are less likely to receive ACE
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inhibitor treatment because of a lower referral rate [28].
It therefore seems more likely that low ACE inhibitor
use in these patients is explained by a general attitude of
using less aggressive treatment in female patients. This
notion is strengthened in our study by the ﬁnding that,
even after adjusting for age, female patients were also
more likely to receive a lower ACE inhibitor dose.
Patients receiving diuretics had a greater chance of
receiving an ACE inhibitor after adjustment for other
comorbidities. Most treatment guidelines recommend
prescription of an ACE inhibitor in addition to a
diuretic, but GPs have expressed the fear of hypotension
and some reluctance to start an ACE inhibitor in pa-
tients already using diuretics [9, 20]. Apparently, these
concerns do not prevent them from prescribing ACE
inhibitors. Patients with a comorbidity of hypertension
were more likely to receive a higher ACE inhibitor dose.
This relationship between concomitant hypertension
and target dose has been observed previously [29] and
may indicate that GPs are less concerned about high
dosages when the patients also have hypertension.
We found few indications that the underuse of ACE
inhibitors could be attributed to previous problems with
these drugs in individual patients. Only for 14 patients
could we determine that an ACE inhibitor had been
discontinued with or without a documented reason. The
use of angiotensin-II-antagonists, which may be con-
sidered as an alternative for patients who cannot tolerate
ACE inhibitors, was small. Of the CHF patients in our
study, 10% were not using any heart failure medication.
It has been suggested that such under-prescribing occurs
especially in patients with relatively minor complaints,
i.e. NYHA classes 1 and 2 [30].
Implications for clinical practice
Patient characteristics such as being a female, older age
and no referral to secondary care were related to under-
prescribing and under-dosing with ACE inhibitors,
while physician characteristics such as physician gender
or experience were not relevant. Interventions in general
practice should therefore not be aimed at speciﬁc GPs,
but at speciﬁc patient groups and should aim to improve
the quality of care especially for women, elderly and
patients without comorbidity. Specialised care, for in-
stance through outpatient clinics, could lead to
improvement of heart failure treatment.
Outside the main focus of this study, these results
indicate the need for better diagnostics in general prac-
tice and better recording of these data to achieve a more
objective diagnosis of CHF.
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